VX-710 has huge potential and the data released to date looks pretty good. Yeah, the run-up to FDA approval (which almost certainly will happen) for VX-478 will cause a gradual increase then a pop in the price (maybe not the 20 points we saw on AGPH the day of approval) but something. I don't think it's in doubt that it will get approval but market share will be an issue given that it doesn't look like it has a different resistance profile than the other PI's. ABT-378 may provide that. Anyway, great stock, and like any biotech it can be a wild ride.